Focal HIFU is “sexual function sparing” in a cohort of 118 selected patients

A new paper in European Urology has suggested that men with localized prostate cancer who are treated by focal forms of high-intensity focused ultrasound (HIFU) have “a return to baseline International Index of Erectile Function — erectile and total International Index of Erectile Function scores” by 6 months after treatment which was maintained at 1 year. … READ MORE …

CureTalk about HIFU for prostate cancer now available on line

Your sitemaster is pleased to be able to report a forthright and interesting discussion yesterday with Dr. Stephen Scionti about the current and future potential of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer. … READ MORE …

Our next prostate cancer CureTalk — with Dr. Stephen Scionti about the role of HIFU

Dr. Stephen Scionti is almost certainly the most experienced practitioner of high-intensity focused ultrasound (HIFU) as a first-line treatment for prostate cancer practicing in the USA today — although he has had to actually treat the vast majority of his patients outside of the USA. … READ MORE …

EDAP TMS submits revised application for approval of their form of HIFU technology

As predicted in yesterday’s post about the nature of the approval of SonaCare Medical’s Sonablate technology as a “generic” form of treatment for prostate tissue ablation, we are likely to see rapid approval of the Ablatherm brand of HIFU technology here in America very soon as well. … READ MORE …

FDA approves HIFU for “prostate tissue ablation”

According to a media release issued by SonaCare Medical early this morning, the company has received approval from the U.S. Food and Drug Administration (FDA) to market its Sonablate® 450 technology in the U.S.A. for prostate tissue ablation. … READ MORE …

Approval of some form of Sonacare Medical’s HIFU technology?

Readers may wish to be aware that your sitemaster has been hearing whispers and rumblings that the U.S. Food and Drug Administration is either about to or has just approved some form of Sonacare Medical’s Sonablate high-intensity focal ultrasound (HIFU) techology for treatment of something related to the prostate. … READ MORE …

Similar long-term outcomes after treatment with HIFU or LDR brachytherapy

The chances that we will ever see a large, randomized, comparative trial of high-intensity focused ultrasound (HIFU) and low-dose-rate (LDR) brachytherapy in the treatment of localized prostate cancer are near to zero. … READ MORE …

Early data from an Australian registry of HIFU-treated patients

We should preface the following commentary by stating that there is no doubt that it takes time to learn to use high-intensity focused ultrasound (HIFU) really well as a form of first-line treatment for localized prostate cancer. This is hardly surprising. … READ MORE …

Combinations of HIFU + radiation as salvage therapy for recurrent prostate cancer

A newly published paper from a clinical research group in Nice, France, has reported very limited data on a small cohort of patients with recurrent localized prostate cancer after first-line therapy who were given salvage therapy using various combinations of radiation therapy and high-intensity focused ultrasound (HIFU). … READ MORE …

Where your $25,000 goes when you get HIFU in Mexico

An article in the Sunday edition of the San Francisco Chronicle has raised questions about how physicians are reimbursed for carrying out high-intensity focused ultrasound (HIFU) procedures on prostate cancer patients in the Caribbean and Mexico. … READ MORE …

Advisory committee votes against approval of SonoCare HIFU

According to a report posted yesterday on the Medscape web site, a Food and Drug Administration (FDA) advisory committee “voted October 1 not to recommend approval, at least for now” of a SonoCare Medical’s Sonablate high-intensity focused ultrasound (HIFU) device to treat patients with radio-recurrent … READ MORE …

Three generations of Sonablate HIFU equipment … the data from Japan

Over the weekend, one of our regular commentators brought to our attention a newly published, retrospective analysis of data on the risks and benefits of treatment of localized prostate cancer with three successive generations of high-intensity focused ultrasound (HIFU) equipment from the company now known as Sonocare Medical. … READ MORE …

FDA advisory committee rejects Ablatherm application

In an entirely unsurprising result yesterday, an advisory committee to the U.S. Food and Drug Administration (FDA) voted very clearly against the approval of EDAP TMS’s Ablatherm technology for treatment of low-risk, localized prostate cancer using high-intensity focused ultrasound (HIFU). … READ MORE …

New Phase I/II trial of InSightec’s MRI-guided focal ultrasound therapy

According to a media release issued yesterday by the City of Hope medical center in Los Angeles, they have become the first center in the USA to treat a patient with focused, MRI-guided, ultrasound technology using the InSightec system. … READ MORE …

Morbidity associated with HIFU at three UK academic centers

A group of three centers in the UK has been investigating the appropriate use of high-intensity focused ultrasound (HIFU) since 2004. … READ MORE …